KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Net Income towards Common Stockholders: 2009-2025

Historic Net Income towards Common Stockholders for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to -$30.7 million.

  • Biomarin Pharmaceutical's Net Income towards Common Stockholders fell 128.98% to -$30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $520.4 million, marking a year-over-year increase of 61.47%. This contributed to the annual value of $426.9 million for FY2024, which is 154.62% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Net Income towards Common Stockholders of -$30.7 million as of Q3 2025, which was down 112.78% from $240.5 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's Net Income towards Common Stockholders' 5-year high stood at $240.5 million during Q2 2025, with a 5-year trough of -$57.9 million in Q4 2021.
  • Its 3-year average for Net Income towards Common Stockholders is $90.0 million, with a median of $88.7 million in 2024.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 440.02% in 2021, then skyrocketed by 8,282.73% in 2023.
  • Biomarin Pharmaceutical's Net Income towards Common Stockholders (Quarterly) stood at -$57.9 million in 2021, then skyrocketed by 99.57% to -$249,000 in 2022, then surged by 8,282.73% to $20.4 million in 2023, then spiked by 513.22% to $124.9 million in 2024, then plummeted by 128.98% to -$30.7 million in 2025.
  • Its last three reported values are -$30.7 million in Q3 2025, $240.5 million for Q2 2025, and $185.7 million during Q1 2025.